Lv6
3030 积分 2024-09-23 加入
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
12天前
已完结
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
12天前
已完结
Azurocidin-1 in neutrophilic airway disease: marker, mediator, or bridge to precision therapy?
1个月前
已完结
Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort study
2个月前
已关闭
Ten unanswered questions about dipeptidyl peptidase-1 inhibition in bronchiectasis
3个月前
已完结
Clearing the air: Clarifying data and interpretations from the ASPEN trial of brensocatib in bronchiectasis
3个月前
已完结
[China lymphoma diagnosis and treatment guideline (2026 edition)]
4个月前
已完结
Diffuse Large B-Cell Lymphoma
4个月前
已完结
One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma
5个月前
已完结
An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II
5个月前
已完结
皖公网安备34019202002308
